INNOVATION IS BOUGHT AND BURIED BY BIG PHARMA ANTICOMPETITIVE MERGERS

INNOVATION IS BOUGHT AND BURIED BY BIG PHARMA ANTICOMPETITIVE MERGERS

by | Apr 22, 2026 | ANTICOMPETITIVE MERGERS, Big Pharma, Dr Simone, Healthcare Costs, HEALTHCARE CRISIS

U.S. antitrust policy should be strengthened to address anticompetitive mergers in the pharmaceutical sector, particularly “killer acquisitions” that eliminate emerging competition. This includes lowering reporting thresholds in highly concentrated health care markets, requiring the inclusion of intangible assets such as patents in merger evaluations, and applying heightened scrutiny to transactions involving overlapping products. Regulators, including the Federal Trade Commission and the Department of Justice, should also require enforceable commitments to continued product development and post-merger transparency. These reforms would help preserve competition, promote innovation, and protect patients from high prices and reduced access to essential therapies.

COVID-19 and the EPSTEIN FILES

COVID-19 and the EPSTEIN FILES

by | Apr 2, 2026 | ACE2, Big Pharma, Bioweapon, CDC, CORONAVIRUS, COVID-19, Dr Simone, FDA, HEALTHCARE CRISIS, VACCINE

The Coronavirus and mRNA patents and medical papers evolved from 1989 onward. In 1999 Bill Gates had to re-brand himself and started Global Alliance for Vaccines and Immunization to market vaccines.

In Feb 2011, he “specifically requested” Epstein’s help. Epstein created a pre-COVID operational structure — financialized, globally coordinated, and partially integrated with Pentagon biodefense systems — that he built, staffed, and rehearsed. Epstein put himself at the junction of these systems, linking philanthropic capital, Wall Street finance, global health governance, and Pentagon biosecurity research.